(Q40493964)

21 September 2017

title

Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects (English)

1 reference

21 September 2017

Patrik Andius

1

1 reference

21 September 2017

Marianne Fehrling

series ordinal

2

1 reference

21 September 2017

Sten Holmäng

series ordinal

3

1 reference

21 September 2017

publication date

1 December 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

96

1 reference

21 September 2017

issue

9

1 reference

21 September 2017

page(s)

1290-1293

1 reference

The quality of life during intravesical bacillus Calmette-Guerin therapy.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05817.X

Beware the BCG failures: a review of one institution's results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05817.X

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05817.X

Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05817.X

10.1111/J.1464-410X.2005.05817.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference